Hormone replacement therapy in healthy BRCA1 and 2 mutation carriers after risk-reducing salpingo-oophorectomy: A 5 Ws and 2 Hs practitioner toolkit.

doi:10.1016/j.maturitas.2026.108982

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Hormone replacement therapy in healthy BRCA1 and 2 mutation carriers after risk-reducing salpingo-oophorectomy: A 5 Ws and 2 Hs practitioner toolkit.

Maturitas - 1 Sept 2026

Bounous Valentina Elisabetta, Andronico Noemi, Lavalle Giulia, Suraci Simona, D'Alonzo Marta, Actis Silvia, Pace Luca, Ferrero Annamaria

Abstract excerpt

The management of menopausal symptoms in healthy women carrying BRCA1 or BRCA2 mutations is clinically challenging, particularly in those undergoing risk-reducing salpingo-oophorectomy. This preventive surgery is recommended because it lowers the risk of ovarian cancer, halves the risk of breast cancer and decreases the risk of all-cause mortality; nevertheless, it induces premature menopause, which does have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Estrogen Replacement Therapy
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Hormone Replacement Therapy

Share to Menopause, Premature

Share to Ovarian Neoplasms

Share to Salpingo-oophorectomy

Source

Open in PubMed

Identifiers

PMID: 42575068
DOI: 10.1016/j.maturitas.2026.108982

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.